Company

Vaxess Technologies

Rocket Ship Rating

Rocket Ship Rating: 94 out of 100

Transforming Delivery and Accessibility of Next-gen Therapies

Also known as Terrestrial, Terrestrial Bio

Biotech & therapeutics
Medical devices & diagnostics
Deeptech
Hardware

Status: Operatingas of 2026-09-17
Business model: B2B
Legal name: Terrestrial Bio

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

Terrestrial is developing the Tacterra™ microarray patch (MAP) platform, capable of delivering a wide range of therapies.

Funding snapshot

Total raised: $138MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
Latest round: Grant, $2.2M2026-06-04

Funding rounds

Grant: $2.2M2026-06-04, Company stated
Round, 2026: $57.3M2026-03-04, SEC form D sold, 16 investors
Round, 2025: $7.9M2025-08-27, SEC form D sold, 4 investors
Round, 2025: $8.4M2025-02-14, SEC form D sold, 3 investors
Round, 2024: $10.8M2024-05-13, SEC form D sold, 6 investors
Round, 2023: $9.1M2023-07-17, SEC form D sold, 4 investors
Round, 2022: $2M2022-09-22, SEC form D sold, 1 investor
Round, 2021: $35M2021-04-29, SEC form D sold, 7 investors
Round, 2021: $2M2021-03-22, SEC form D sold, 3 investors
Round, 2019: $3.6M2019-02-06, SEC form D sold, 4 investors
Round, 2016: $863K2016-12-27, SEC form D sold, 2 investors
Round, 2013: $1.2M2013-05-21, SEC form D sold, 2 investors

Products

Hardware: Tacterra microarray patch (MAP) platform